Why Kinder Morgan Canada (TSX:KML), Bausch Health (TSX:BHC), and Ceridian HCM (TSX:CDAY) Raced Ahead on the TSX Wednesday

The TSX had a good day Wednesday gaining 0.59%. South of the border, the S&P 500 gained 0.82% on the day while the Dow raced ahead 0.93%.

Dollar symbol and Canadian flag on keyboard

Image source: Getty Images

The markets had a good day Wednesday, as the TSX gained 0.59%, the S&P 500 was up 0.82%, and the Dow gained 0.93%.

Investors continue to debate where interest rates are headed. The minutes from the most recent meeting of the Federal Reserve suggest even they’re not so sure. 

Despite the lack of confidence from investors, these three stocks raced ahead on the TSX Wednesday.

Kinder Morgan Canada 

Kinder Morgan Canada (TSX:KML) jumped 32% Wednesday on the $4.3 billion takeover offer from Pembina Pipeline (TSX:PPL)(NYSE:PBA).

Under the terms of the deal, Pembina will pay 0.3068 of one of its shares for each share of Kinder Morgan Canada. That’s approximately $15.02 per KML share. In addition, Pembina will pay $2.1 billion for the 2,900-kilometre Cochin pipeline that runs from Fort Saskatchewan, Alberta, to Riga, Michigan. 

Kinder Morgan, which owns 70% of Kinder Morgan Canada, will get a stake in Pembina worth $1.2 billion. 

Pembina wouldn’t have done the deal if the U.S. portion of the Cochin pipeline wasn’t included in the purchase. 

“I suspect Pembina was pretty adamant that they do include that and eventually there was enough pressure in the process,” Raymond James analyst Chris Cox said. “The valuation seems fair; they are definitely good assets.”

With Pembina one of the few producers winning on the markets in 2019, the latest news ought to be good for the long-term trajectory of its stock.

Bausch Health

Bausch Health (TSX:BHC)(NYSE:BHC) gained 5.4% on Wednesday closing out trading at $29.83, up 18% year to date through August 21. 

Although there wasn’t any news that would have moved Bausch stock by more than 5% on Wednesday, it’s probably still basking in the glow of strong second-quarter results and increased guidance for the remainder of fiscal 2019. 

“Our strong second-quarter results demonstrate that our team’s efforts to pivot to offence continue to gain traction,” CEO Joseph Papa said on a conference call August 6. 

The company expects to generate at least US$8.4 billion in revenue in 2019 along with US$3.4 billion in adjusted EBITDA. 

Since Papa took over in 2016, the company has focused on reducing its debt while concentrating on growing its “significant seven,” which includes its optical products and treatments for glaucoma and bloodshot eyes. 

Ceridian HCM

Ceridian HCM (TSX:CDAY)(NYSE:CDAY) saw its shares rise 4.3% Wednesday to $75.35. 

Like Bausch Health, Ceridian’s move had less to do with specific news and more to do with its second-quarter earnings report from July 30. 

The company’s Dayforce cloud-based human capital management software continues to capture the interest of more and more businesses around the world. In the second quarter, Dayforce’s revenue grew 27.1% to US$134.5 million. Its Dayforce recurring revenue grew even more impressively, growing by 32.1% year over year excluding currency. 

As a result of its strong start to the fiscal year, the company expects Dayforce to grow revenues by between 29% and 31% in the second half of the year. 

Ceridian’s stock will continue to ride the success of Dayforce. Until its growth slows, expect more impressive quarterly reports in the future.  

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Will Ashworth has no position in any stocks mentioned. The Motley Fool owns shares of Bausch Health Companies and Kinder Morgan. Pembina is a recommendation of Dividend Investor Canada.

More on Investing

bulb idea thinking

The Top Stocks to Buy With $500 Right Now

You don’t need to break the bank with these stocks. Find out why all three of these picks deserve a…

Read more »

Dividend Stocks

A Dividend All-Star I’d Buy Over Shopify Stock Any Day

Are you interested in Shopify stock? Here’s one dividend all-star I’d buy before it!

Read more »

think thought consider
Dividend Stocks

Up 14% in 2023, Is BAM Stock Still a Buy Today?

BAM (TSX:BAM) stock remains up 14% in the last year, but has been a bit confusing for investors wondering whether…

Read more »

A bull and bear face off.

The Silver Lining of Bear Markets: Opportunities for Long-Term Canadian Investors

Long-term Canadian investors should embrace bear markets as opportunities to buy quality stocks at discounts.

Read more »

A worker overlooks an oil refinery plant.
Dividend Stocks

3 Top Infrastructure Stocks I’d Buy for 2024 and Beyond

Canadian infrastructure stocks like Enbridge Inc (TSX:ENB) often offer high yields.

Read more »

Businessman and engineer handshake closing a deal in construction site

2 Top Industrial Stocks to Buy on the TSX Today

Here are two of the top industrials stocks on the TSX long-term investors can consider buying at current levels for…

Read more »

exchange-traded funds
Dividend Stocks

The Rise of Dividend ETFs in Canada: A New Era of Investment

Sick of picking individual dividend stocks? These three ETFs cater to a wide range of dividend investing strategies.

Read more »

edit CRA taxes
Dividend Stocks

How to Earn $250 of Monthly Passive Income That the CRA Won’t Tax

Many Canadians don't even know they can earn income TAX-FREE! Here's one way to earn an extra $250/month of safe,…

Read more »